AliveCor competitors

A Strategic and Operational CFO with broad & deep geographic and business experience in Pharmaceutical, Biotech, Medical Device & Consumer Goods leading international markets worldwide in Financial operations, General Management, Information Technology, Procurement & Facilities. A strategic thinker partnering with leadership to develop long-range plans and deliver business & financial results through fact-based decision support, developing diverse cross-functional talent and implementing comprehensive metrics. Identify and sponsor change through P&L efficiencies, improved cash flow and new business models, fueling profit growth and margin expansion. Appling this approach to lead “beyond the numbers” with broad business acumen to impact the business.Recognized as a thought leader and business partner with a hands-on approach going beyond the financial leader role, a strong communicator who sorts through complexity and asks the right questions, willing to challenge the status quo & lead transformational change. Develop global finance organizations, placing leaders beyond the finance function.Experienced Management Board member of various sized healthcare, life science and consumer goods companies from start-up to multi-billion dollar global market leaders, driving high-growth businesses, improving turn-arounds and acquisition integration. Led financial organizations from 5 to 200 employees.Areas of expertise:Growth Strategies | Global Leadership | Board Member | Fact-Based Decision Support | Strategic & Financial Planning | Worldwide P&L Management | International Finance | Cost Accounting | Competitive Intelligence | Talent DevelopmentAdditional skills:Internal Financial Controls | Financial & Portfolio Analysis | Tax Planning | International Treasury Functions | Capital Structure & Cash Management | Mergers & Acquisition | Project Management | Investor Relations | New Product Launches | Acquisition Integration

Mr. Michael Klein serves as the Chairman and CEO for iCAD Medical (Nasdaq: ICAD), a clinical artificial intelligence company focused on the detection of breast cancer and other proliferative diseases. iCAD's, therapy subsidiary, Xoft Inc. uses novel electronic brachytherapy for the treatment of breast and gynecological cancers as well as brain, rectal and prostate cancers. Between December 2014 and October 2018, when he assumed the above position, Mr. Klein served as Chief Executive Officer at Inflection Point Consulting, an executive coaching and consulting firm with a focus on medical technology, biopharma and healthcare services. During this same time period, Mr. Klein served as a Adjunct Professor at the Leavey School of Business at Santa Clara University. Prior to that, from December 2011 to November 2014. Klein was the Chief Executive Officer at SonaCare Medical, LLC (f/k/a US HIFU, LLC), a global leader in minimally invasive high intensity focused ultrasound technologies used for the treatment of prostate and other urological cancers. From April 2011 to December 2011, Mr. Klein was the President of the Civco Radiation Oncology Division within Roper Industries, a diversified industrial company that produces engineered products for global niche markets. He was President and Chief Executive Officer of Xoft, Inc., a medical device company, a position he held from December 2004 until the sale of Xoft to iCAD Medical in December 2010. Prior to joining Xoft, from 2000 to 2004, Mr. Klein served as Chairman, President and Chief Executive Officer of R2 Technology, Inc., a breast and lung cancer computer aided detection company. The first company to bring a medical artificial intelligence technology before the FDA and receive PMA Regulatory Approval. Previously, Mr. Klein served in VP, Sales and Marketing roles at Varian Medical Systems (VAR) and Becton Dickinson (BDX). Mr. Klein received a Bachelor of Arts degree from the University at Albany, SUNY. Mr. Klein also received his M.B.A. from the New York Institute of Technology and completed his post-graduate Executive Education Studies at Harvard University and Babson College. Mr. Klein lives in Mountain View, California with his wife and 3 children, in close proximity. Mr. Klein splits time between iCAD headquarters in Nashau, NH and Xoft’s headquarters in San Jose, CA.

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors. Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.

John F. Sheridan has served as our President and Chief Executive Officer since March 2019 and as a member of our Board of Directors since June 2019. Prior to joining our company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation (NASDAQ: VOLC), a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company. From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors. Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for the overall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998. In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee. A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.